C5 and paroxysmal nocturnal hemoglobinuria: To that end, this study aimed to estimate the contemporary prevalence of PNH and describe HRU and direct healthcare costs associated with C5 inhibitors among patients with PNH treated with eculizumab or ravulizumab in US clinical practice using a large commercial health plan data source.